Gonadotropic Axis, Bone Mass, and Sarcopenia Assessment After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma.
Christianne Tolêdo de Souza LealViviane Angelina de SouzaJúlia Diniz FerreiraAlexandre ZaniniKelli Borges Dos SantosDanielle Guedes Andrade EzequielAbrahão Elias Hallack NetoPublished in: Clinical transplantation (2024)
Gonadal dysfunction, the most frequent endocrine complication in both sexes after autologous hematopoietic cell transplant (HCT) could increase bone loss and sarcopenia, a disease characterized by reduced muscle strength and mass. Sarcopenia is associated with worse survival, lower remission rates, and progression-free survival in patients with lymphoma after HCT. Low bone mass affected approximately 20% of the transplanted patients within 2 years and harms quality of life. This study was conducted in a single center and identified a strong relationship with patients transplanted more recently by LEC (lomustine, etoposide, and cyclophosphamide) conditioning regimen with sarcopenia. Peripheral neuropathy and bone mass changes were also associated with sarcopenia as well, suggesting a relationship with muscle strength loss.
Keyphrases
- bone loss
- end stage renal disease
- skeletal muscle
- free survival
- ejection fraction
- chronic kidney disease
- bone marrow
- bone mineral density
- peritoneal dialysis
- prognostic factors
- cell therapy
- low dose
- stem cells
- community dwelling
- cell proliferation
- signaling pathway
- body composition
- systemic lupus erythematosus
- postmenopausal women
- single cell